Benchmark upgraded Codexis to Buy from Hold.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CDXS:
- Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Codexis, Roche in licensing deal for newly engineered double-sranded DNA Ligase
- Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
- Codexis to Participate in TD Cowen 44th Annual Health Care Conference
- CDXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?